FIG. 2.

Binding IgG response against the rpC2-C3 polypeptide and gp125t in BALB/c mice immunized with different HIV-2ALI antigens. Four mice were immunized with each vaccine regimen. For all mice, the schedule of immunization included one priming and two boosting at days 14 and 28. Fourteen days after each immunization, sera were collected and assayed for the presence of binding IgG antibodies to rpC2-C3 polypeptide and soluble gp125t. Mice antiserum at a 1:100 dilution was added to rpC2-C3 polypeptide (A)- or gp125t (B)-coated microplates, and alkaline phosphatase (AP)-conjugated goat anti-mouse IgG was added as a secondary antibody. (C) Endpoint antibody titers against rpC2-C3 after the last immunization (boost II). (D) Endpoint antibody titers against gp125t after the last immunization (boost II). The boxes in panels A and B indicate the median antibody responses and standard deviations. The lines in panels C and D indicate the median antibody responses.